Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
May 2023
-
Story Live Magazine
The future of medicine is here
An essay by Vas Narasimhan, CEO of Novartis about the historical context and coming innovations in medicine with an introduction by Goran Mijuk.
-
Statement
CHMP recommends revoking the conditional marketing authorization for Adakveo® (crizanlizumab)
-
Press release
Sandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMA
Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for… -
Press release
New Sandoz Board of Directors appointed
Novartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2… -
Press release
Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III… -
Press release
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
Sandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansion Sandoz gains access to proprietary AI-driven technology platform… -
Story Patient Perspectives
Q&A: Addressing unmet needs for people living with PNH, a rare and chronic blood disorder
Hear from Director of Patient Services at AAMDSIF on how she supports patients with PNH, a blood disorder that significantly impacts quality of life.
-
Press release
Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
Agreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology. Products from Adalvo slated for near- to mid-term launches, with four out of six…
April 2023
-
Press release
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase… -
Press release
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of… -
Press release
Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase… -
Ad hoc release
Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz wuchs im ersten Quartal um +8% (kWk1, +3% USD), und das operative Kernergebnis verbesserte sich um +15% (kWk, +8% USD) Innovative…